GA
REGN icon

Geller Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Geller Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-258
Closed -$271K – 273
2024
Q3 		$271K Buy
258
+7
+3% +$7.79K 0.02% 221
2024
Q2 		$264K Hold
251
– – 0.02% 226
2024
Q1 		$242K Buy
251
+15
+6% +$14.3K 0.02% 241
2023
Q4 		$207K Buy
+236
New +$194K 0.02% 257
2023
Q2 		– Sell
-261
Closed -$214K – 254
2023
Q1 		$214K Buy
+261
New +$197K 0.03% 164
2022
Q1 		– Sell
-371
Closed -$234K – 186
2021
Q4 		$234K Buy
371
+4
+1% +$2.46K 0.05% 147
2021
Q3 		$222K Buy
+367
New +$228K 0.05% 139

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geller Advisors's REGN Position: Q4 2024 in Review

Geller Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 258 shares — an estimated $271K sold.

Geller Advisors first reported a position in REGN in Q3 2021 and held it in 7 quarters. The position peaked at $271K in Q3 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Geller Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Geller Advisors sold 258 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $271K.
  • Geller Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • Geller Advisors's Regeneron Pharmaceuticals position peaked at $271K in Q3 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Geller Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.